IVI [to 16 January 2016]
http://www.ivi.org/web/www/home

.
[Undated]
New affordable oral cholera vaccine receives prequalification by the World Health Organization
– Oral cholera vaccine manufactured by Korean company EuBiologics following technology transfer from the International Vaccine Institute (IVI)
– Vaccine developed through international public-private partnership involving IVI and EuBiologics
– Euvichol will be used to protect the world’s underprivileged populations from cholera

SEOUL, KOREA – EuBiologics Co., Ltd. (EuBiologics) and the International Vaccine Institute (IVI) announced today that Euvichol®, an inactivated oral cholera vaccine (OCV), recently received prequalification from the World Health Organization (WHO). Developed to protect against epidemic and endemic cholera, the two-dose oral vaccine is low-cost and ready to use in a single-dose vial, facilitating its use in mass immunization programs in low-income countries.

“I am very pleased that Euvichol®, a vaccine whose development was enabled by IVI, was prequalified by WHO,” said Dr. Jerome Kim, IVI’s Director General. “This milestone shows that public-private partnerships – such as that between IVI and EuBiologics – are effective in developing vaccines against diseases of the poor like cholera.”…

…“The prequalification of Euvichol® demonstrates the power of partnerships to successfully develop vaccines,” said Dr. Anita Zaidi, Head of Enteric and Diarrheal Diseases at the Bill & Melinda Gates Foundation. “We are pleased to be a part of this effort and congratulate IVI and Eubiologics for this major milestone. Euvichol®will go a long way in easing global cholera vaccine supply constraints at the global level, however a lot remains to be done to make sure the cholera vaccine will be used in populations and countries where cholera is a problem.”